These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 7736543)

  • 1. ADEPT and related concepts.
    Bagshawe KD
    Cell Biophys; 1994; 24-25():83-91. PubMed ID: 7736543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of antibody-enzyme conjugate clearance by investigation of prodrug and active drug in an ADEPT clinical study.
    Springer CJ; Poon GK; Sharma SK; Bagshawe KD
    Cell Biophys; 1994; 24-25():193-207. PubMed ID: 7736524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo.
    Rogers GT; Burke PJ; Sharma SK; Koodie R; Boden JA
    Br J Cancer; 1995 Dec; 72(6):1357-63. PubMed ID: 8519645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy.
    Fang L; Sun D
    Drug Metab Dispos; 2008 Jun; 36(6):1153-65. PubMed ID: 18356268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for enzyme/prodrug cancer therapy.
    Xu G; McLeod HL
    Clin Cancer Res; 2001 Nov; 7(11):3314-24. PubMed ID: 11705842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-enzyme conjugates for cancer therapy.
    Melton RG; Sherwood RF
    J Natl Cancer Inst; 1996 Feb; 88(3-4):153-65. PubMed ID: 8632489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
    Biela BH; Khawli LA; Hu P; Epstein AL
    Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
    Springer CJ; Niculescu-Duvaz I
    Anticancer Drug Des; 1995 Jul; 10(5):361-72. PubMed ID: 7639927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody directed enzyme prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects.
    Bagshawe KD; Sharma SK; Springer CJ; Rogers GT
    Ann Oncol; 1994 Dec; 5(10):879-91. PubMed ID: 7696159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy.
    Sharma SK; Bagshawe KD; Burke PJ; Boden JA; Rogers GT; Springer CJ; Melton RG; Sherwood RF
    Cancer; 1994 Feb; 73(3 Suppl):1114-20. PubMed ID: 8306255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.
    Wolfe LA; Mullin RJ; Laethem R; Blumenkopf TA; Cory M; Miller JF; Keith BR; Humphreys J; Smith GK
    Bioconjug Chem; 1999; 10(1):38-48. PubMed ID: 9893962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjugates of COL-1 monoclonal antibody and beta-D-galactosidase can specifically kill tumor cells by generation of 5-fluorouridine from the prodrug beta-D-galactosyl-5-fluorouridine.
    Abraham R; Aman N; von Borstel R; Darsley M; Kamireddy B; Kenten J; Morris G; Titmas R
    Cell Biophys; 1994; 24-25():127-33. PubMed ID: 7736516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A monoclonal antibody against human beta-glucuronidase for application in antibody-directed enzyme prodrug therapy.
    Haisma HJ; Van Muijen M; Scheffer G; Scheper RJ; Pinedo HM; Boven E
    Hybridoma; 1995 Aug; 14(4):377-82. PubMed ID: 8522350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
    Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG
    Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-directed enzyme prodrug therapy (ADEPT). A three-phase study in ovarian tumor xenografts.
    Sharma SK; Boden JA; Springer CJ; Burke PJ; Bagshawe KD
    Cell Biophys; 1994; 24-25():219-28. PubMed ID: 7736526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumour disease.
    Blakey DC; Burke PJ; Davies DH; Dowell RI; Melton RG; Springer CJ; Wright AF
    Biochem Soc Trans; 1995 Nov; 23(4):1047-50. PubMed ID: 8654679
    [No Abstract]   [Full Text] [Related]  

  • 17. Selective activation of anthracycline prodrugs for use in conjunction with ADEPT.
    HariKrishna D; Rao AR; Krishna DR
    Drug News Perspect; 2003 Jun; 16(5):309-18. PubMed ID: 12942162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.
    Sharma SK; Bagshawe KD
    Expert Opin Biol Ther; 2017 Jan; 17(1):1-13. PubMed ID: 27737561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prodrugs in cancer chemotherapy.
    Connors TA; Knox RJ
    Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.